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Background: Hyperuricemia is a risk factor for the onset of chronic kidney disease (CKD) and is significantly
associated with the progression of CKD. However, there is no sufficient evidence by interventional research
supporting a cause-effect relationship. Hyperuricemic patients without gouty arthritis, whose serum urate (SUA)
concentration is ≥8.0 mg/dL and who have a complication, are treated by pharmacotherapy in addition to lifestyle
guidance. Nevertheless, there is no evidence that rationalizes pharmacotherapy for patients with hyperuricemia
who have no complication and whose SUA concentration is below 9.0 mg/dL.
Methods/Design: The FEATHER (FEbuxostat versus placebo rAndomized controlled Trial regarding reduced renal
function in patients with Hyperuricemia complicated by chRonic kidney disease stage 3) study is a prospective,
multicenter, double-blind, randomized, placebo-controlled trial of febuxostat—a novel, nonpurine, selective,
xanthine oxidase inhibitor. The present study will enroll, at 64 medical institutions in Japan, 400 Japanese patients
aged 20 years or older who have hyperuricemia without gouty arthritis, who present CKD stage 3, and whose SUA
concentration is 7.1-10.0 mg/dL. Patients are randomly assigned to either the febuxostat or the control group, in
which febuxostat tablets and placebo are administered orally, respectively. The dosage of the study drugs should
be one 10-mg tablet/day at weeks 1 to 4 after study initiation, increased to one 20-mg tablet/day at weeks 5 to 8,
and elevated to one 40-mg tablet/day at week 9 and then maintained until week 108. The primary endpoint is
estimated glomerular filtration rate (eGFR) slope. The secondary endpoints include the amount and percent rate
of change in eGFR from baseline to week 108, the amount and percent rate of change in SUA concentration from
baseline to week 108, the proportion of patients who achieved an SUA concentration ≤6.0 mg/dL, and the
incidence of renal function deterioration.
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Discussion: The present study aims to examine whether febuxostat prevents a further reduction in renal function
as assessed with eGFR in subjects and will (1) provide evidence to indicate the inverse association between a
reduction in SUA concentration and an improvement in renal function and (2) rationalize pharmacotherapy for
subjects and clarify its clinical relevance.
Trial registration: UMIN Identifier: UMIN000008343
Keywords: Xanthine oxidase inhibitor, Urate-lowering therapy, Reduced renal function, Hyperuricemia,
Chronic kidney disease, Randomized controlled study, PlaceboBackground
Hyperuricemia is defined as ‘serum urate (SUA) concen-
tration >7.0 mg/dL’ [1]. The prevalence of hyperuricemia
is 21.5% in Japanese adult men, and hyperuricemia
prevails most in patients in their 30s and 40s; the pre-
valence of hyperuricemia is 30% in patients in their 30s
[2]. Hyperuricemia is a risk factor for the onset of
chronic kidney disease (CKD) [3] and is significantly
associated with the progression of CKD [4,5]. Persisting
hyperuricemia causes the tissue deposition of monoso-
dium urate monohydrate crystals in extracellular fluids
of the joints and other sites and induces urate deposition
diseases (e.g., gouty arthritis, tophi, kidney injury, and
urolithiasis) [6,7]. Women are at higher risk of experien-
cing the progression of reduced renal function at an
SUA concentration ≥6.0 mg/dL that is lower than the
conventional definition of hyperuricemia [3], and hyper-
uricemia influences the progression of kidney injury at
the early phase of CKD [8]. In addition to the provision of
lifestyle guidance (diet therapy, drinking restriction, encour-
agement of physical activity, patient education on treatment
objective, and management of comorbidities), pharmaco-
therapy with urate-lowering drugs is recommended for (1)
hyperuricemic patients with gouty arthritis or tophi, for
(2) hyperuricemic patients whose SUA concentration is
8.0 mg/dL or higher and who have a complication (e.g.,
kidney injury, urolithiasis, hypertension, ischemic heart
disease, diabetes mellitus, metabolic syndrome), and for
(3) hyperuricemic patients whose SUA concentration is
9.0 mg/dL or higher and who have no complications [9].
Allopurinol, a purine inhibitor of xanthine oxidase
(XO) conventionally used for urate-lowering therapy
(ULT) to inhibit uric acid synthesis, was suggested to
slow a reduction in renal function compared with the
control group in a 12-month, prospective, randomized
controlled trial (RCT) in 54 hyperuricemic patients with
CKD [10] and delayed a reduction in renal function com-
pared with the control group in a 24-month, prospective
RCT in 113 patients with CKD stage 3 [11]. Because of
the open-label nature, however, these small-size single-
center clinical studies did not provide sufficient evidence
about the effect of allopurinol to prevent renal function
reduction.A novel urate-lowering drug, febuxostat, is a potent
non-purine selective inhibitor of XO and inhibits both
the reduced and oxidized forms of the enzyme in con-
trast to allopurinol that inhibits the reduced form of
the enzyme only [12]. Febuxostat is metabolized
mainly by glucuronidation and oxidation in the liver
[13], has its dual (urinary and fecal) pathways in excre-
tion (urinary and fecal excretion rates: 49.1% and
44.9%, respectively) [14], and is effective and well tol-
erated in patients with mild to moderate renal and
hepatic impairment [15]. A 28-day, Phase II, random-
ized clinical trial of febuxostat in 153 patients with
gout [16] indicated that treatment with febuxostat sig-
nificantly reduced SUA concentrations at doses of 40,
80, and 120 mg daily and was safe and well tolerated.
The post-hoc analysis [17] of a clinical study on the
long-term (5-year) oral administration of febuxostat in
116 patients with hyperuricemic gout [18] revealed
that the maintenance of or an improvement in eGFR
was inversely correlated with a quantitative reduction
in SUA from baseline. Therefore, we presumed that
continuous lowering of SUA concentrations might
deter a further reduction in renal function of patients
with hyperuricemia and/or gout and recognized the
importance of prospectively evaluating the long-term
effect of SUA reduction on renal function in hyper-
uricemic patients with impaired renal function.
The objective of the present study is to examine
whether febuxostat prevents a further reduction in renal
function as assessed with eGFR in Japanese patients with
hyperuricemia, who have never had gout and are com-
plicated by CKD stage 3.
Methods/Design
Study design and study organization
The FEATHER study is a prospective, multicenter,
double-blind, randomized, placebo-controlled clinical
study (Figure 1). The recruitment of patients started in
November 2012 and concluded in December 2013. The
scheduled study period including the 1-year recruitment
period is 3 years. Steering Committee (Additional file 1)
prepared the protocol and will assume the roles, inclu-
ding the solution of interpretational questions about the
Randomization through the dynamic 
allocation procedure using allocation 
factors (study site, gender, age, 
serum uric acid, proteinuria, and
complication by diabetes mellitus)
Placebo group (N = 200)
10-mg tablet/day at weeks 1-4 after initiation
20-mg tablet/day at weeks 5-8 after initiation
40-mg tablet/day thereafter
Febuxostat group (N = 200)
10-mg tablet/day at weeks 1-4 after initiation
20-mg tablet/day at weeks 5-8 after initiation
40-mg tablet/day thereafter
Study drug administration for 108 weeks
Primary endpoint: eGFR slope (mL/min/1.73 m2/year)
Randomization
N = 400, 1:1
Patients with asymptomatic hyperuricemia complicated by chronic kidney disease stage 3
Figure 1 Flow diagram of the FEATHER study.
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institutions, and other tasks. Executive Committee will
assume the roles, including the conduct and administra-
tion of the entire study, the regulatory check of study
progress, the examination of study-propelling measures,
the recognition of problems in conducting the study, the
discussion on problem-solving measures, the adjustment of
publication (article contribution and academic announce-
ment), and other tasks. Independent Data and Safety
Monitoring Committee will assume the roles, including the
monitoring of study progress, the assessment of safety data
at appropriate intervals, the recommendation to continue,
adjust, or discontinue the study, and other tasks. The study
was approved by Ethics Review Boards of the participating
medical institutions (Additional file 2) and is being
conducted according to the Declaration of Helsinki. All
patients should provide written informed consent before
enrollment.
Patients
The FEATHER study will consecutively recruit, at 64
medical institutions in Japan, 400 Japanese patients with
hyperuricemia who have never had gout and are com-
plicated by CKD stage 3a or 3b, who are aged 20 years
or older, and who have no gouty arthritis (Table 1).
Treatment
Study treatment
Patients are randomly assigned to either of the febuxo-
stat or the control group, in which febuxostat tablets
and placebo are administered orally, respectively. Pa-
tients in the study groups will receive the allocated study
drug for 108 weeks. The dose of the study drugs should
be one 10-mg tablet/day at weeks 1 to 4 after study initi-
ation, increased to one 20-mg tablet/day at weeks 5 to 8,
and elevated to one 40-mg tablet/day at week 9 and then
maintained until week 108.Concomitant therapy
During the study period, the investigator provides the
enrolled patient with lifestyle guidance (recommendation
for diet management, restriction of alcohol consump-
tion, and encouragement of exercise) by use of a leaflet
prepared for this study. The administration of urate-
lowering drugs (allopurinol, benzbromarone, probenecid,
bucolome, and febuxostat except for study treatment)
and contraindicated drugs of febuxostat (mercaptopu-
rine hydrate, azathioprine, vidarabine, and didanosine) is
prohibited during the study period.
Blinding
All parties involved in the present study (patients, investi-
gators, and data analysts) will be blinded to the allocation
of the study drugs—febuxostat tablets and placebo. Serum
and urinary urate concentrations will be measured at the
central laboratory. The measured values of serum and
urinary urate will be concealed to the investigator and pa-
tient in an attempt to keep the allocation blinded. Labora-
tory tests at respective medical institutions will exclude
the measurement of SUA concentration and urinary urate
concentration from the assessment items. Furthermore,
the following actions will be taken to ensure the
safety of the patient when SUA concentrations change
as described below:
1. The investigator will be informed when
SUA concentrations measured at the
central laboratory exceeded 12.0 mg/dL in
a patient and will discontinue this study
for the relevant patient;
2. Independent Data and Safety Monitoring
Committee will monitor SUA concentrations
and will examine a trend, if detected, to
increase in SUA concentrations in each
study group; and
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Men and women 1. Uncontrolled diabetes mellitus; HbA1c: ≥8.0% (JDS) or ≥8.4% (NGSP)
2. Age ≥20 years at informed consent 2. Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg
3. Patients with hyperuricemia; serum uric acid: 7.1-10.0 mg/dL 3. ALT or AST: greater than twice the upper limit of institutional reference range
4. eGFR: 30–59 mL/min/1.73 m2 (CKD stages 3a and 3b) 4. Change in serum creatinine level by more than 50% within 12 weeks before
the confirmation of eligibility
5. No history of gout 5. Acute renal disease, nephrotic syndrome, other serious disease, dialysis,
or renal transplantation
6. Written informed consent for study enrollment obtained
from the patient
6. Complication or history of malignant tumor (not excluded from the study
when the malignant tumor is not treated within 5 years and if there is
no recurrence)
7. History of hypersensitivity to febuxostat
8. Intake of any one or more of the following drugs at the confirmation of eligibility:
mercaptopurine hydrate, azathioprine, vidarabine, and didanosine
9. Intake of any one or more of the following urate-lowering drugs within 4 weeks
before the confirmation of eligibility: allopurinol, benzbromarone, probenecid,
bucolome, and febuxostat
10. Initiation of intake, dose modification, or discontinuation of intake of any one or
more of the following drugs within 4 weeks before the confirmation of
eligibility: losartan, fenofibrate, thiazide diuretics, and loop diuretics
11. Continuous intake of salicylic acid drugs, e.g., aspirin (the patient taking low-dose
aspirin [≤324 mg/day] need not to be excluded from the study)
12. Hormone replacement therapy with estrogens
13. Pregnancy, nursing, or planed pregnancy during the study
14. Enrollment in other clinical trials within 24 weeks before providing informed consent
15. Ineligibility at the investigator’s discretion
CKD, chronic kidney disease; Hba1c, hemoglobin A1c; JDS, Japan Diabetes Society; NGSP, National Glycohemoglobin Standardization Program.
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concentrations decreased to 2.0 mg/dL or lower in a
patient and will address the change appropriately.Randomization
Patients, who meet all inclusion criteria and who do not
fall under any exclusion criterion, are consecutively en-
rolled and randomly assigned at a 1:1 ratio to receive
febuxostat or placebo through the dynamic allocation
method using the following six background factors ac-
cording to the minimization method: study site, gender,
age (<65 or ≥65 years), SUA concentration (<8.0 mg/dL
or ≥8.0 mg/dL), qualitative proteinuria (present or absent),
and complication by diabetes (present or absent).Endpoints
The primary endpoint of the FEATHER study is eGFR
slope (change in eGFR per year, mL/min/1.73 m2/year)
during the 108-week study period. The eGFR is cal-
culated with the following equation defined by the
Japanese Society of Nephrology: eGFRcreat (mL/min/
1.73 m2) = 194 × [serum creatinine (mg/dLs) measured by
the enzyme method]-1.094 × age-0.287 (× 0.739 if the patient
is female).The secondary endpoints are as follows: (1) the
amount (mL/min/1.73 m2) and rate (%) of change in
eGFR from baseline to weeks 24, 48, 72, and 108; (2) the
amount (mg/dL) and the rate (%) of change in SUA con-
centration from baseline to week 108; (3) the proportion
of patients whose SUA concentration became ≤6.0 mg/dL;
(4) the incidence of renal deterioration defined by the
commencement of dialysis or doubled serum creatinine
concentration; (5) changes in biomarkers for renal
function (serum cystatin C), oxidative stress (urinary
8-hydroxydeoxyguanosine and urinary L-type fatty
acid-binding protein), and inflammation (serum C-react-
ive protein), as well as in variables for cardiovascular
events (12-lead electrocardiogram, serum N-terminal pro-
brain natriuretic protein, and albumin urine/creatinine
ratio) to monitor the outcomes of ULT from baseline to
week 108; (6) incidence of gouty arthritis; and (7) inci-
dence of adverse events (AEs).
For safety assessment, AEs should be evaluated on
clinical examination and in laboratory tests. The en-
rolled patient should visit the institution once every 4
weeks during the first 3 months and once every 3
months thereafter (Table 2). The investigator should
evaluate patient compliance through history taking at
each visit.







Visita 1 2 3 4 5 6 7 8 9 10 11 12 13
Week after treatment onseta −4 0 4 8 12 24 36 48 60 72 84 96 108
Acquisition of informed consent X
Pregnancy testb, gender, and date of birth X
Smoking history, anamnesis, and complications X
Status of study drug intake X X X X X X X X X X X
Status of concurrent therapyc X X X X X X X X X X X X X
Commencement of dialysis X X X X X X X X X X X
Development of gouty arthritis X X X X X X X X X X X
Development of adverse events X X X X X X X X X X X
Height (second visit only), body weight, and BMI X X X
Blood pressure (systolic, diastolic) and pulse rate Xd X X X X X X X X X X X X
12-lead electrocardiogram Xe Xf
Hematology blood chemistryg, and urinalysish Xd X X X X X X X X X X X X
Blood Serum uratei and creatinine concentrations Xd √ √ √ √ √ √ √ √ √ √ √ √
T-C, HDL-C, and TG √ at fasting
HbA1c Xj √ √ √
Markersk √ √ √
Urine Urinary creatinine, albumin, and uratei
concentrations
√ √ √
Markersk √ √ √
Blood sampling volume for measurement a
t the central laboratory (mL)
16 10 10 10 10 10 16 10 10 10 10 16
X: Measurement at the institution’s laboratory; √: Measurement at the central laboratory.
aCorresponds to the time of completion, discontinuation, or withdrawal.
bFor the premenopausal female patient only.
cAntihypertensives, antihyperlipidemics, antidiabetics, non-steroidal anti-inflammatory drugs, adrenocortical steroids, theophylline, colchicine, and part of contrain-
dicated and restricted concurrent therapies.
dBlood pressure, serum urate concentration, serum creatinine concentration, alanine aminotransferase, and aspartate aminotransferase are required to confirm
eligibility. Urine protein (qualitative) is required to adjust allocation.
eData obtained within 6 months before consent acquisition should be acceptable, unless cardiovascular or other events have developed. Data within 3 months
before and after study completion should be acceptable.
fRed blood cell count, white blood cell count, platelet count, hemoglobin, and hematocrit.
gAlanine aminotransferase, aspartate aminotransferase, γ-glutamyl transpeptidase, blood urea nitrogen, creatine kinase, and blood electrolytes (Na, K, and Cl).
hUrine protein, urine glucose, occult blood reaction, urine pH, and N-acetylglucosaminidase.
iSerum urate concentration and urinary urate concentration should be measured at the central laboratory only during the study period. Measurement results
obtained at the central laboratory should be transmitted to the institutions, but serum urate concentration and urinary urate concentration should not.
jShould be measured for the patient who is suspected of having diabetes.
kSerum cystatin C, urinary 8-hydroxy-2’-deoxyguanosine, urinary liver-type fatty acid-binding protein, serum C-reactive protein, and serum N-terminal pro-brain-type
natriuretic peptide.
BMI, body mass index; T-C, total cholesterol; HDLC, high-density lipoprotein cholesterol; TG, triglyceride.
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The statistical analysis of the primary endpoint should
be made to demonstrate the superiority of febuxostat to
placebo. The linear regression line will be fitted to the
longitudinal data of the eGFR for each patient. In
patients with CKD stage 3, the intergroup difference in
the eGFR slope should be compared between the febuxo-
stat group and the control group according to Student’s
t-test (analysis of variance), with the stratified adjust-
ment of stages 3a and 3b. Subgroup analysis by stage3a and 3b should be conducted to check the hetero-
geneity of the effect size.
Based on previous study results [11,19], we calculated
a sample size of 89 patients to detect a difference of
2.7 mL/min/1.73 m2/year in eGFR slope between the
study groups at each CKD stage (3a or 3b), with a stand-
ard deviation of 7.2, a power of 80%, and a one-sided
significance level of 0.05. This sample size will provide
94.2% power at a two-sided significance level of 0.05 to
perform intergroup comparisons in the overall cohort of
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group; 356 patients in total). Assuming a withdrawal
rate of 11%, the target number of patients is 100 in
the subgroups of patients with CKD 3a and 3b, respect-
ively, leading to 200 patients required for the study
groups, respectively, and to a total of 400 patients with
CKD stage 3.
Efficacy analysis should be performed on an intention-
to-treat principle basis. All patients, who took at least
one dose of the study drug and who have at least one
measurement of the eGFR after study drug adminis-
tration, should be included in the efficacy analysis set.
All patients who took at least one dose of the study drug
should be included in the safety analysis set. The interim
analysis is not planned in this study. The data to be
collected in the present study will be managed and
analyzed by the following organization that is com-
pletely independent from the present study’s organiza-
tions: Non-Profit Organization Japan Clinical Research
Support Unit.
Discussion
In addition to the traditional risk factors for cardiovas-
cular disease (CVD) (e.g., smoking, older age, male gen-
der, hypertension, diabetes mellitus, physical inactivity,
menopause, and hyperlipidemia), reduced renal function
is an important risk factor for CVD [20-25]. CKD, when
advanced to stage 4 or 5, requires the commencement
of dialysis and extensively elevates the risk of death
from CVD. Recently, reduced renal function [26] and
CKD stage 3 [27,28] were found to be risk factors for
end-stage kidney disease (ESKD). In clinical settings,
however, patients with CKD are more likely to die of
CVD than to develop ESKD [29,30]. An eGFR below
60 mL/min/1.73 m2 is a risk factor for the onset of
CVD [9], and reduced renal function increases the
risk of developing cardiovascular death [31]. In Japan,
nevertheless, pharmacotherapy is currently not recom-
mended for hyperuricemic patients without gouty
arthritis who have an SUA concentration below 8.0 mg/dL
and for those without gouty arthritis who have no compli-
cation (e.g., CKD) and an SUA concentration below
9.0 mg/dL [2]. In Western countries, pharmacotherapy for
asymptomatic hyperuricemia is not proactively recom-
mended. This negative approach is attributable to the
absence of evidence by interventional research on the
causality between reduced renal function and the onset of
CVD. The target SUA concentration is 6.0 mg/dL or
below for hyperuricemic patients with gouty arthritis but
is not established for patients with asymptomatic hyper-
uricemia. Therefore, hyperuricemic patients without gouty
arthritis are managed fundamentally through lifestyle
guidance to lower SUA concentrations in clinical settings.
In patients with CKD stage 3, the causes of reduced renalfunction should be scrutinized, and multidisciplinary
treatment is recommended to prevent renal function re-
duction [9].
Following the >40-year period during which allopur-
inol (marketed in 1966) was available as the only XO
inhibitor, febuxostat was approved in 2009 in the USA
for the chronic management of hyperuricemia in
patients with gout. Oxypurinol, the active metabolite of
allopurinol, exerts the XO-inhibitory activity (the Kd
value: 0.54 nmol/L) by binding to the reduced form of
XO (Mo(IV)) through a strong covalent bond [32]. How-
ever, the covalent bond disappears and oxypurinol is
released because Mo (IV) is reoxidized with time and
returns back to the oxidized form of XO (Mo (VI) whose
half-life is 300 min at 25°C), and enzyme activity thus
recovers [33]. Febuxostat presents striking contrast to
oxypurinol because of its strong binding to enzyme pro-
teins through multiple interactions, e.g., ionic bond,
multiple hydrogen bonds, and hydrophobic interactions.
Therefore, febuxostat does not depend on the oxidized
or reduced form of XO and is strongly bound to both
the oxidized and reduced forms of XO, thus inhibiting
the enzyme for a long period of time and translating into
its obvious therapeutic advantages [34]. Furthermore,
febuxostat has high enzyme selectivity because of min-
imal effects on enzymes other than XO involved in the
purine and pyrimidine metabolism [12,35]. Moreover, rat
models, in which oxonic acid is used to induce hyperuri-
cemia [36,37], indicate that hyperuricemia provokes a
diversity of pathophysiological changes, e.g., activation
of the renin-angiotensin system, decreased creatinine
clearance, and severe arteriolopathy of the afferent ar-
teriole [36-38]. Experimental studies afforded evidence
that allopurinol and febuxostat, when used before the
development of irreversible histological damage in the
vasculature and glomeruli, can reverse these adverse
changes, thereby preventing renal function reduction
[39,40]. In addition, mild to moderate renal impair-
ment has little effect on the pharmacodynamics and
pharmacokinetics of febuxostat [41,42]. These experi-
mental and clinical findings drove us to investigate
the effect of early ULT with febuxostat on hyperu-
ricemia complicated by renal impairment in clinical
settings.
The present study, designed as a randomized placebo-
controlled study and based on the presumed inverse
correlation between eGFR and SUA concentration, is the
first to prospectively assess the long-term (2-year) effect
of SUA reduction on renal function in hyperuricemic
patients with concurrent renal impairment. It is less
common to prescribe allopurinol for gout patients with
moderate renal impairment [43,44]. Hence, we consider
that our study aiming at investigating the long-term effect
of ULT with febuxostat to prevent a further reduction in
Hosoya et al. Trials 2014, 15:26 Page 7 of 9
http://www.trialsjournal.com/content/15/1/26renal function of hyperuricemic patients with moderately
impaired renal function affords a new design approach
and would be of clinical relevance.
Two large-scale RCTs published before the approval of
febuxostat by the Food and Drug Administration [45,46]
demonstrated that febuxostat 80 mg daily more effect-
ively lowered SUA concentrations than did allopurinol
300 mg daily. In an 8-week, double-blind, randomized,
allopurinol-controlled clinical trial in 244 patients with
gout, febuxostat 40 mg daily showed a significantly more
potent urate-lowering effect than allopurinol 200 mg daily
[47]. A 6-month, large-scale, RCT of febuxostat 40/80 mg
or allopurinol 300 mg (200 mg in moderate renal impair-
ment) was conducted in 2,269 patients with gout and
SUA ≥8.0 mg/dL [48]; the study indicated (1) the equiva-
lent UL efficacy and comparable safety for febuxostat
40 mg daily and allopurinol 300/200 mg daily, (2) the
significantly greater efficacy of febuxostat 40 mg daily in
lowering SUA than allopurinol in patients with mildly or
moderately impaired renal function, (3) comparable safety
at the doses examined, and (4) the favorable tolerability of
febuxostat 40 mg daily, especially for gout patients
with mild or moderate renal impairment. The large-
scale RCTs of febuxostat conducted to date [45,46,48]
reported treatment-related AEs, the majority of which
were mild to moderate in severity (e.g., liver function
test abnormalities, diarrhea, nausea, headache, joint-
related signs and symptoms, and rashes); the major
serious AEs were non-specific bacterial infections,
coronary artery disease, ischemic coronary artery dis-
orders, and so on. Hence, there is a battery of experi-
mental and clinical evidence to design an RCT in
hyperuricemic patients with moderate renal impairment
(30–59 mL/min/1.73 m2).
Our study has several limitations. Only hyperuricemic
patients, who have never had gout and are complicated
by CKD stage 3, are being enrolled in the present study.
Therefore, no clinical evidence will be obtained for
patients with severer CKD—stage 4 or 5. Under a benefi-
cial medical insurance system in Japan (the universal
healthcare insurance system), furthermore, patients who
are willing to participate in a double-blind, randomized,
placebo-controlled clinical study are represented by a
particular population of patients with asymptomatic
hyperuricemia complicated by stage 3 CKD. In this
sense, selection bias cannot be ruled out.
In conclusion, we expect that the present study would
show an inverse association between a reduction in SUA
concentration and an improvement in renal function
and will rationalize pharmacotherapy for subjects. There-
fore, the early commencement of ULT for them may help
to maintain renal function, to prevent the progression
of CKD, and to improve renal prognosis in efforts to
prevent CVD.Trial status
Recruitment and enrollment started in November 2012
and concluded in December 2013.
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